Can Pfizer's new Crohn's data help Inflectra pry away Remicade market share?

30th October 2017 Uncategorised 0

Pfizer, which is struggling to build traction for its Remicade biosimilar in the U.S., has some new data it hopes can make a difference in building sales for its Inflectra.

More: Can Pfizer's new Crohn's data help Inflectra pry away Remicade market share?
Source: fierce